Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials.
Flupirtine as neuroprotective add-on therapy in autoimmune optic neuritis.
Dimethyl fumarate inhibits the expression and function of hypoxia-inducible factor-1α (HIF-1α).
Assessment of structural and functıonal vısual outcomes ın relapsıng remıttıng multıple sclerosıs wıth vısual evoked potentıals and optıcal coherence tomography.
Magnetic resonance imaging outcomes from a phase III trial of teriflunomide.
More Than 15 Years of Experience with Intradetrusor OnabotulinumtoxinA Injections for Treating Refractory Neurogenic Detrusor Overactivity: Lessons to Be Learned.
Patient trial of immunization to treat Alzheimer’s disease begins at Cedars-Sinai
Altered intra- and interregional synchronization in relapsing-remitting multiple sclerosis: a resting-state fMRI study.
CXCR7 Is Involved in Human Oligodendroglial Precursor Cell Maturation.
A case of posterior reversible encephalopathy syndrome associated with gilenya(®) (fingolimod) treatment for multiple sclerosis.
Morphogenesis of the demyelinating lesions in Baló's concentric sclerosis.
Zebrafish as a model to investigate CNS myelination.
Switch to natalizumab vs fingolimod in active relapsing-remitting multiple sclerosis.
Burden of neurological conditions in Canada.
Alkali metals levels in the human brain tissue: Anatomical region differences and age-related changes.
Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study.
Genzyme Announces Successful Phase III Results for Alemtuzumab (LEMTRADA TM*) in Multiple Sclerosis
Use of interleukin-2 for management of natalizumab-associated progressive multifocal leukoencephalopathy: case report and review of literature.
Evaluation of quality of life and fatigue in radiologically isolated syndrome.
Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity.
Biogen Idec and Abbott Announce Enrollment of First Patient in Global Phase III Study of Daclizumab for Relapse Remitting Multiple Sclerosis
Treatment with Trichuris suis soluble products during monocyte-to-macrophage differentiation reduces inflammatory responses through epigenetic remodeling.
Dimethyl fumarate attenuates cerebral edema formation by protecting the blood-brain barrier integrity.
The low EOMES/TBX21 molecular phenotype in multiple sclerosis reflects CD56+ cell dysregulation and is affected by immunomodulatory therapies.
Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype.

Pages